{"chat": [{"from": "Andrew", "title": "Hello", "to": "Andrew", "location": "Prince George", "date": "04-27-2023", "message": "This is a test message", "type": "message", "id": 1}, {"title": "Remdesivir dosing", "to": "Everyone", "location": "", "date": "08-07-2023", "message": "Was the second group of Remdesivir doses meant for eGFR < 30 mL/min? (200mg IV, than 100mg IV once at 48 or 72 hours)", "type": "Doctor", "by": "wphan"}, {"title": "Dosing", "to": "Everyone", "location": "UHNBC", "date": "10-07-2023", "message": "The dosing is a bit confusing as I believe the second dosing set should be for eGFR less than 30 mL/min and would be q48h or q72h dosing interval.", "type": "Pharmacist", "by": "Sumeet Hayer"}, {"title": "COVID-19, Remdesivir (RDV)", "to": "Everyone", "location": "UHNBC", "date": "17-07-2023", "message": "In July 2023 the FDA approved RDV use regardless of GFR, including those patients on HD. The FDA approval was based on phase 1 and phase 3 REDPINE trials which showed the pharmacokinetics and safety profile in patients with severe renal impairment.\n\n", "type": "Doctor", "by": "Abu Hamour"}, {"title": "Spelling Mistake", "to": "Everyone", "location": "", "date": "22-07-2023", "message": "Just noticed Placeholder was misspelt", "type": "Pharmacist", "by": "Sumeet Hayer"}, {"title": "", "to": "Everyone", "location": "PRRH", "date": "22-07-2023", "message": "similar comments - the 2nd section for eGFR is meant to say <30 for eGFR I believe. As per Dr. Hamour's point - this may be a distinction we no longer need to have in this order set.", "type": "Doctor", "by": "Salpy Kelian"}]}